Last update 02 Feb 2026

Lilly SA

Subsidiary Company|1953|Spain|
www.lilly.es

Overview

Tags

Other Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
no Data
No Data
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
Small molecule drug1
Top 5 TargetCount
NET(Norepinephrine transporter)1

Related

1
Drugs associated with Lilly SA
Atomoxetine Hydrochloride
Target
NET
Mechanism
NET inhibitors
Active Org.
Hyloris Pharmaceuticals SAHyloris Pharmaceuticals SA [+4]
Originator Org.
Eli Lilly & Co.Eli Lilly & Co.
Active Indication
Attention Deficit Disorder With Hyperactivity
Inactive Indication
Alzheimer Disease [+12]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date26 Nov 2002
14
Clinical Trials associated with Lilly SA
EUCTR2010-019724-30-ES
/ CompletedPhase 4
Comparación de insulina lispro premezclada (proporción baja) dos veces al día frente a insulina glargina una vez al día e insulina lispro prandial una vez al día, como estrategias de intensificación de la insulinoterapia en pacientes con diabetes tipo 2 que presentan un control glucémico inadecuado con insulina glargina y metformina y/ó pioglitazona Comparison of Twice-Daily Insulin Lispro Low Mixture versus Once-Daily Basal Insulin Glargine and Once-Daily Prandial Insulin Lispro as Insulin Intensification Strategies in Patients with Type 2 Diabetes who have Inadequate Glycemic Control on Basal Insulin Glargine and Metformin and/or Pioglitazone
EUCTR2009-014958-16-ES
/ CompletedPhase 2
A 12-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2599506 in Patients with Type 2 Diabetes Mellitus Treated with Diet and Exercise, with or without Metformin Estudio de fase 2, aleatorizado, doble ciego, de 12 semanas de duración, controlado con placebo, de LY2599506 en pacientes con diabetes mellitus tipo 2 tratados con dieta y ejercicio, con o sin metformina
EUCTR2007-004950-10-ES
/ CompletedPhase 2
Pemetrexed con suplemento simplificado de folato y dexametasona frente a pemetrexed con suplemento estándar como segunda línea de quimioterapia en pacientes con cáncer de pulmón no microcítico Pemetrexed with simplified folate and dexamethasone supplementation versus pemetrexed with standard supplementation as second-line chemotherapy for patients with non-small cell lung cancer
100 Clinical Results associated with Lilly SA
Login to view more data
0 Patents (Medical) associated with Lilly SA
Login to view more data
100 Deals associated with Lilly SA
Login to view more data
100 Translational Medicine associated with Lilly SA
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Feb 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
1
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Atomoxetine Hydrochloride
 ( NET )		Attention Deficit Disorder With Hyperactivity
More
Approved
Dasolampanel
 ( AMPA receptor x GluR-5 )		Pain
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free